RSS   Newsletter   Contact   Advertise with us
Post Online Media

Pliant Therapeutics appoints Suzanne Bruhn to board of directors

Suzanne BruhnPliant Therapeutics, Inc., an early-stage biotechnology company, announced the appointment of Suzanne Bruhn to its board of directors.
Article continues below

READ MORE Aeglea BioTherapeutics appoints Suzanne Bruhn to board

Dr. Bruhn most recently served as president and CEO of Promedior, Inc., a privately held, clinical-stage immunotherapy company pioneering the development of targeted therapeutics to treat diseases involving fibrosis.

There, she successfully negotiated an exclusive agreement with Bristol Myers Squibb for the right to acquire Promedior.

Prior to Promedior, Dr. Bruhn spent 13 years at Shire Human Genetic Therapies (HGT), a division of Shire PLC, where she held a series of positions of increasing responsibility before serving as senior vice president of strategic planning and program management.

Currently, Dr. Bruhn serves on the board of directors of Raptor Pharmaceuticals (NASDAQ: RPTP), a commercial-stage, biopharmaceutical company developing therapeutics for orphan diseases.

Dr. Bruhn received a Bachelor’s degree from Iowa State University, a Ph.D. from the Massachusetts Institute of Technology and was a postdoctoral fellow at Harvard Medical School.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy